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Purpose: To identify the underlying genetic causes of fundus albipunctatus (FA), a rare form of congenital stationary
night blindness that is characterized by the presence of white dots in the midperiphery of the retina and delayed dark
adaptation, in Pakistan.
Methods:  Two  families  with  FA  were  identified  by  fundus  examination,  and  genome-wide  single  nucleotide
polymorphism  genotyping  was  performed  for  two  individuals  from  family  A  and  six  individuals  from  family  B.
Genotyping data were subsequently used to identify the identical homozygous regions present in the affected individuals
of both families using the online homozygosity mapping tool Homozygosity Mapper. Candidate genes selected from the
homozygous regions were sequenced.
Results: Three identical homozygous regions were identified in affected persons of family A (on chromosomes 8, 10,
and 12), whereas a single shared homozygous region on chromosome 12 was found in family B. In both families, the
homozygous region on chromosome 12 harbored the retinol dehydrogenase 5 (RDH5) gene, in which mutations are known
to  be  causative  of  FA.  RDH5  sequence  analysis  revealed  a  novel  five  base  pair  deletion,  c.913_917delGTGCT
(p.Val305Hisfs*29), in family A, and a novel missense mutation, c.758T>G (p.Met253Arg), in family B.
Conclusions: We identified two novel disease-causing RDH5 mutations in Pakistani families with FA, which will improve
diagnosis and genetic counseling, and may even lead to treatment of this disease in these families.
Fundus albipunctatus (FA; OMIM:136880), or flecked
retina disease, was described for the first time by Lauber [1].
FA is a rare form of congenital stationary night blindness and
is characterized by the presence of typical white dots on the
whole fundus or concentrated in the midperipheral region of
the retina, with or without macular involvement, and a delay
in dark adaptation. The inheritance pattern of FA is autosomal
recessive [2-5]. In one family, a male and his two daughters
showed FA, which could be due to autosomal dominant or
pseudodominant (i.e., autosomal recessive) inheritance [6].
Mutations in three genes–retinol dehydrogenase 5 (RDH5),
retinaldehyde-binding protein 1 (RLBP1), and retinal pigment
epithelium–specific  protein  (RPE65)–are  known  to  be
associated with FA [7-10]. Retinitis punctata albescens has
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similar phenotypic characteristics but is progressive in nature
and is mostly caused by mutations in RLBP1 [8].
FA-causing  mutations  were  first  identified  in  RDH5,
which  is  expressed  predominantly  in  the  retinal  pigment
epithelium (RPE) [7]. RDH5 encodes an enzyme that is part
of the visual cycle, which involves a series of specialized
enzymes and retinoid binding proteins that are essential for
the regeneration of the 11-cis retinal chromophore [11-14].
RDH5 consists of 318 amino acids and is highly conserved
among different species [15]. Within the RPE cells, RDH5
resides in the smooth endoplasmic reticulum [16] where it is
principally  involved  in  chromophore  regeneration  by
catalyzing the final step in the biosynthesis of 11-cis retinal
[7,17-20].
The current study explores the molecular mechanisms
behind FA in Pakistani families, using high-density single
nucleotide polymorphism (SNP) microarrays and sequence
analysis  of  known  FA  genes  located  in  the  identified
homozygous regions. Using this approach, we identified two
novel mutations in RDH5 in two families with FA.
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Approval of the study: Approval for this study was granted by
the Ethics Committee/Institutional Review Board of Shifa
College of Medicine/Shifa International Hospital, Islamabad.
Signed informed consent was obtained from members of both
families participating in the current study.
Family collection and clinical evaluation: Families A and B
(Figure 1) reside in remote areas of Pakistan and were part of
Figure 1. Pedigrees and sequencing results. A: Segregation of the mutation in family A. B: Segregation of the mutation in family B. C and
D: Sequence electropherograms of affected individuals carrying homozygous variants (upper panels) and unaffected heterozygous carriers
(middle panels) of families A (C) and B (D), along with the results of a control individual (wild-type [wt], lower panels). Arrows point to the
probands; individuals tested with single nucleotide polymorphism (SNP) microarrays are indicated with asterisks.
Molecular Vision 2012; 18:1558-1571 <http://www.molvis.org/molvis/v18/a161> © 2012 Molecular Vision
1559a  cohort  of  83  families  with  retinitis  pigmentosa  and
associated  retinal  diseases.  Blood  samples  were  collected
from affected and normal individuals of both families and
DNA was extracted by a standard protocol [21]. Pedigrees
were  drawn  using  Haplopainter  [22].  Both  families  were
clinically  evaluated  by  fundus  examination;  in  addition,
electroretinography (ERG) measurements were recorded for
family A.
Homozygosity  mapping  analysis:  All  affected  individuals
from both families and one healthy person from family B were
subjected  to  high-density  HumanOmniExpress  (>700  K;
Illumina  Inc.,  San  Diego,  CA)  single  nucleotide
polymorphism (SNP) microarray analysis. Genotyping data
were analyzed with the online tool Homozygosity Mapper
[23]. Haplotypes of affected and normal individuals were
compared in each family to identify the identical homozygous
regions shared by all affected individuals.
Primer design and RDH5 sequence analysis: The online tool
Primer3 [24] was used to design PCR primers (Table 1). The
five  exons  of  RDH5,  including  their  flanking  exon-intron
boundaries, were amplified by PCR using standard conditions
and  reagents.  PCR-amplified  exonic  fragments  were
electrophoretically separated on 2% agarose gels containing
ethidium  bromide  and  DNA  bands  were  visualized  under
ultraviolet transillumination. PCR clean-up purification plates
(NucleoFast® 96 PCR; Cat. No. 743100.10, Macherey-Nagel,
Düren, Germany) were used to purify the amplified fragments
according to the manufacturer’s protocol. Briefly, 20 µl of
each amplified PCR product was transferred to Nucleofast 96
PCR plate. Wells were filled up to 100 µl volume with RNase-
free water to ensure the uniform loading. Contaminants were
removed  by  ultrafilteration  with  the  help  of  a  vacuum
apparatus for 10 min. Thirty µl of RNase-free water was
poured in each well and DNA was recovered by thorough
mixing with a multi-channel pipette. Sanger sequencing was
then  performed  with  Big  Dye  Terminator  version  3  and
analyzed on a 3730 DNA analyzer (Applied Biosystems, Inc.,
Foster City, CA).
Vector  NTI  Advance  (TM)  2011  software  from
Invitrogen Corporation (Carlsbad, CA) was used to analyze
the sequencing results of RDH5 exons.
In silico analysis: Sorting Intolerant from Tolerant (SIFT),
Polymorphism Phenotyping v2 (Polyphen-2), and Mutation
Taster  [25]  were  used  to  assess  the  possible  pathological
nature of the missense variant identified in this study. Project
HOPE [26] was used to analyze and predict the structural
variations in mutant RDH5.
Amino  acid  conservation:  RDH5  protein  sequences  from
different  species  including  human  (H.  sapiens,
ENSP00000257895),  macaque  (M.  mulatta,
ENSMMUP00000017380),  mouse  (M.  musculus,
ENSMUSP00000026406),  dog  (C.  familiaris,
ENSCAFP00000000084),  cow  (B.  taurus,
ENSBTAP00000056512),  cat  (F.  catus,
ENSFCAP00000012945),  tetraodon  (T.  nigroviridis,
ENSTNIP00000022889),  and  round  worm  (C.  elegans,
F35B12.2) were aligned using Vector NTI Advance™ 2011
to  check  the  evolutionary  conservation  of  the  substituted
amino acid in RDH5.
RESULTS
Clinical studies: Initial symptoms of visual complaints in
patients  from  both  families  were  observed  from  early
childhood.  Fundus  examination  of  affected  individuals
revealed  the  presence  of  white  dots  typical  of  FA  in  the
midperiphery of the retina (Figure 2; Table 2). ERG responses
of cone and rod photoreceptors were diminished in affected
individual IV-1 of family A (Table 3). This individual had
daytime  vision  problems,  which  confirms  that  cone
photoreceptors were also affected. Macular degeneration was
also observed in individual IV-1 of family A and individual
IV-7 of family B. ERG results were not available for family
B.  The  visual  acuity  (VA)  of  affected  individual  IV-7  of
family B was different from the VAs of other individuals
(VI-2, VI-3) of this family, and the density of white dots was
also  variable,  which  indicates  intrafamilial  phenotypic
variability.  Affected  individuals  of  family  B  had  normal
daytime vision.
Genetic studies: In family A, three homozygous regions were
identified that were shared by the affected persons (Figure
3A). The largest homozygous region spanned 24.5 Mb (hg19:
3.3–27.8 Mb; flanked by SNPs rs4881131 and rs10764698)
on  chromosome  10.  The  second  and  third  homozygous
regions  were  10.5  Mb  (hg19:  46.4–56.9  Mb;  flanked  by
rs11183300 and rs7314300) and 8.1 Mb (hg19: 25.9–34.0 Mb;
flanked by rs9521585 and rs9555687) in length, and were
located on chromosomes 12 and 8, respectively. The second
largest region (10.5 Mb) on chromosome 12 harbored the FA-
associated gene RDH5. RDH5 sequence analysis identified a
TABLE 1. PRIMER SEQUENCES OF RDH5.
Exon Forward primer (5′-3′) Reverse primer (5′-3′) Amplified fragment length (bp)
1 CTAGGCAAATCTGGCCTCTG GGTCCACCTCAGAGTTGTGG 396
2 GGAAAGGGCTTGAGGGC GACTGTGGGGATCAGGACAC 450
3 CTCCCAGGAAGAAGAGGGAG CACCTCTGCTGGCCCAC 399
4 ATGTCCCTCAAAGTCCCCTC AGGCTTATGCAGGACTGGC 301
5 GGCCCCAGAAGACAGTACC CGTGCAGCTGTAGATGTGAG 589
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1560Figure 2. Fundus photographs of affected individuals from both families. A, B: Right and left eye, respectively, of affected individual IV-1
of family A (see arrow, Figure 1A). C, D: Right and left eye, respectively, of affected individual IV-7 of family B (see arrow, Figure 1B).
E, F: Right and left eye, respectively, of affected individual VI-2 of family B. G, H: Right and left eye, respectively, of affected individual
VI-3 of family B.
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1561novel  homozygous  5  bp  deletion  (c.913_917delGTGCT;
p.Val305Hisfs*29) in family A (Figure 1C).
The mutation c.913_917delGTGCT (p.Val305Hisfs*29)
segregated in family A (Figure 1A) was consistent with an
autosomal  recessive  inheritance  pattern.  Both  affected
individuals carried this mutation in a homozygous state, while
both parents and an unaffected brother carried this variant
heterozygously. The mutation causes a frameshift in the open
reading frame and results in the replacement of the last 14
amino acids of the RDH5 protein by 28 aberrant amino acids.
This mutation is predicted to affect part of the transmembrane
domain and elongate the cytosolic C-terminal tail. As this
deletion  is  located  in  the  last  exon  of  RDH5,  nonsense-
mediated decay of the mutant mRNA is not predicted.
In family B homozygosity mapping revealed an 8.9 Mb
(hg19:  52.6–61.5  Mb)  homozygous  segment  (Figure  3B)
flanked by SNPs rs1894035 and rs1395538, encompassing the
RDH5  gene.  RDH5  sequence  analysis  revealed  a  novel
homozygous missense mutation (c.758T>G; p.Met253Arg) in
this family. Segregation analysis confirmed that all affected
individuals  were  homozygous  for  the  mutation  c.758T>G
(p.Met253Arg; Figure 1B), suggesting that this variant may
be disease causing. The methionine at position 253 is a highly
conserved amino acid residue among different species (Figure
4),  and  c.758T  is  an  evolutionarily  highly  conserved
nucleotide  with  a  phyloP  score  of  4.40.  SIFT  predicted
p.Met253Arg  to  be  a  deleterious  (score:  0.05)  mutation,
Polyphen  classified  this  mutation  as  probably  damaging
(score: 0.992), and Mutation Taster predicted this mutation to
be disease causing. Structural analysis showed that there was
a difference in charge and size of the wild-type Met253 and
the  mutant  Arg253.  The  wild-type  residue  is  uncharged,
whereas the mutant residue is positively charged. The wild-
type residue is buried in the alpha helix and the mutant residue
introduces a charge in this buried residue in the core of the
protein or protein complex, which can lead to misfolding of
the protein. The mutant residue is bigger and probably will
not fit in the core of the protein. The hydrophobicities of the
wild-type and mutant residue also differ, and therefore, this
mutation is likely to cause the loss of hydrophobic interactions
in the core of the protein.
Ethnically matched control samples were not tested for
these mutations; however, neither variant was found in dbSNP
nor in 1000 Genomes.
DISCUSSION
In this study, we have identified two novel disease-causing
mutations in RDH5 in two unrelated consanguineous families
with FA. Both families exhibited typical FA, as was evident
from the presence of typical white dots in the midperipheral
regions of the retina. In both families, the older patients–IV-1
in family A and IV-7 in family B–had macular degeneration,
which might suggest a progressive disease course in these
families.
Including our findings, 36 different mutations in RDH5
associated with FA have been identified to date [7,27-48]. FA
patients carrying RDH5 mutations exhibit high phenotypic
variability,  ranging  from  nonprogressive  to  progressive
disease, a variable VA, variation in the density of white dots,
and occasionally macular involvement. FA with or without
cone dystrophy has also been reported with varying degrees
of severity [30,37,48]. A total of 85 FA patients from 68
different  families  carrying  RDH5  mutations  have  been
identified globally (Table 4, Table 5, and Table 6). These
persons were found to exhibit a high variability in phenotype,
but the presence of white dots was a common feature. In
comparing the different phenotypes and genotypes associated
with RDH5, it is difficult to establish a valid and clear-cut
genotype-phenotype correlation.
RDH5 is a transmembrane enzyme with a membrane-
embedded N-terminal domain, a catalytic ectodomain, a C-
terminal transmembrane domain, and a cytosolic tail [16]. The
topology of retinol dehydrogenases has been controversial as
human  retinal  reductase  1  [49]  and  mouse  retinol
dehydrogenase 1 [50] have been reported to have a membrane-
embedded  N-terminal  domain  but  no  C-terminal
transmembrane segment, which supports the presence of a
cytosolic  ectodomain.  RDH5  was  suggested  to  have  a
cytosolic ectodomain without any C-terminal transmembrane
domain [50]. However, another retinol dehydrogenase, cis-
retinol/androgen  dehydrogenase  1  (CRAD1),  has  been
described in detail to have a RDH5-like structure with both a
luminal ectodomain and cytosolic C-terminal domain, and a
similar topology has been suggested for most of the retinol
TABLE 2. CLINICAL FEATURES OF AFFECTED INDIVIDUALS IN BOTH FAMILIES.
Individual Age (years) VA (RE, LE) Fundus phenotype RPE degeneration Retinoscopy
Family A, IV-1 35 6/12, 6/12 White dots, macular degenerative
changes
Yes Not determined
Family B, IV-7 45 6/18, 6/12 White dots, macular degenerative
changes
Yes Hypermetropia
Family B, VI-2 17 6/6, 6/6 White dots, macula healthy No Low hypermetropia
Family B, VI-3 10 6/6, 6/6 White dots, macula healthy No Low hypermetropia
          LE, left eye; RE, right eye; RPE, retinal pigment epithilium; VA, visual acuity.
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1563dehydrogenases  [51].  The  frameshift  mutation
p.Val305Hisfs*29 identified in family A is located in the C-
terminal transmembrane domain, while the missense mutation
p.Met253Arg is located in the catalytic ectodomain of RDH5
(Figure  5).  As  the  C-terminal  transmembrane  region  is
necessary  to  retain  CRAD1  in  the  endoplasmic  reticulum
[51], the RDH5 mutation p.Val305Hisfs*29 might affect the
endoplasmic reticulum localization of RDH5. Moreover, an
elongated C-terminal cytosolic tail might also create problems
in  the  proper  functioning  of  RDH5,  as  the  C-terminus  is
thought to play a role in enzymatic activity and localization
of CRAD1 and RDH5 [51].
Structural  analysis  of  RDH5  performed  with  Project
HOPE suggests that the missense mutation p.Met253Arg may
cause misfolding of the RDH5 protein because of the loss of
hydrophobic interactions in the core of the mutant protein.
Misfolding of the mutant protein may cause it to degrade
[52-54]. Absence of RDH5 leads to the accumulation of 11-
cis retinol [20] in the RPE, and a reduction of 11-cis retinal in
Figure  3.  Homozygosity  mapping
results. A: Plot of homozygous regions
identified  in  affected  individuals  in
family A using Homozygosity Mapper
analysis. B: Plot of homozygous regions
identified  in  affected  individuals  in
family B using Homozygosity Mapper
analysis.  The  red  lines  indicate
homozygous regions shared by affected
individuals in each family. The arrows
indicate  the  homozygous  regions  that
harbor RDH5.
Figure 4. Amino acid conservation of
amino  acids  245–260  of  RDH5  in
different  species.  Gray  shading
indicates amino acids that are identical
to human RDH5 amino acids.
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1567the  photoreceptors,  which  in  turn  might  result  in  the
malfunctioning of rod and cone photoreceptor cells.
RDH5-associated disease can be prevented with proper
genetic  counseling  of  carriers  of  RDH5  mutations,  and
persons with this disease can be treated with 9-cis-β-carotene
supplementation. Rdh−/− mice were successfully treated with
9-cis  retinal  [55],  and  9-cis-β-carotene  was  given  to  FA
patients leading to major visual improvements [56]; 9-cis-β-
carotene is converted to 9-cis retinal [57,58], which is more
stable than 11-cis retinal [59]. The higher stability of opsin
bound to 9-cis retinal slows down the visual cascade and thus
minimizes the toxicity of accumulating by-products in the
visual  cycle  [55,60,61].  In  the  rod-photoreceptor  outer
segments 9-cis retinol will be converted to all-trans retinal
during bleaching. This is subsequently reduced to all-trans
retinol  and,  in  the  RPE,  all-trans  retinol  is  isomerically
converted to 9-cis, 11-cis, and 13-cis retinol. A stereospecific
enzyme,  9-cis  retinol  dehydrogenase,  is  reported  to  be
involved in the synthesis of 9-cis retinoic acid by oxidizing 9-
cis retinol [62], and 9-cis retinal treatment is suggested to
induce  the  endogenous  synthesis  of  11-cis  retinal  by  its
interaction with the retinoid X nuclear receptor [56,59,63].
Based on our and other studies, we estimate that FA
contributes  to  approximately  2%  (4/208)  of  families  with
retinal dystrophy in Pakistan and a total of 17 patients have
been identified with FA [9]. Two FA families have been
reported  to  carry  RLBP1  mutations  [9],  while  two  other
families with FA have RDH5 mutations (this study). In the
current study, we have identified seven additional FA patients
who are candidates for 9-cis-β-carotene therapy.
In  conclusion,  we  have  identified  two  novel  disease-
causing  mutations,   c.913_917delGTGCT
(p.Val305Hisfs*29) and c.758T>G (p.Met253Arg),  in    two
Pakistani families with FA. Our study expands the current
mutation spectrum of RDH5 and contributes to the existing
body of knowledge. In addition, this study will help clinicians
to improve the diagnosis of FA by differentiating FA from
retinitis punctata albescens, providing genetic counseling and
prescribing the correct treatment to patients.
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